Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com
30 signals in the last 90 days.
The order this company entered each market — oldest to newest
Harbour BioMed Appoints Dr. Patel Advisor
Harbour BioMed Appoints Dr. Patel Advisor
Sign up to see the full signal feed
How Harbour BioMed's international expansion compares to its competitors
Harbour BioMedYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Harbour BioMedYou | 3 | 0 | +36% | 26 | 50 |
Director-Senior Director, Corporate Development (APAC)
View postingXuhui District, Shanghai, China · last mo.
Senior IP Counsel
View postingShanghai, China · 4mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Harbour BioMed appointed Dr. Adam Zong as President to strengthen pipeline, advance portfolio strategy, and lead partnerships. Zong brings 20+ years biopharma experience from Merck, BMS, Pfizer, and Hengrui Therapeutics.
Harbour BioMed's Phase I trial of HBM9378, a novel antibody targeting TSLP, shows favorable safety and extended half-life, supporting further development for severe immunological disorders.
HBM9378 Phase I trial shows good safety and extended half-life, supporting further evaluation in severe immune diseases.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Harbour BioMed's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
